New Dual-Action drug shows promise for kidney cancer patients
NCT ID NCT07488572
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a new medicine called AK112 (Yivoximab) for people with advanced kidney cancer that has spread. The drug works in two ways: it helps the immune system attack cancer cells and blocks blood vessels that feed tumors. About 60 participants will receive the drug every three weeks to see if tumors shrink or stop growing. The goal is to find a better first-line treatment for those who cannot take standard therapies.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Yivoximab (AK112)
- What this could lead to
- If successful, this could offer a new first-line treatment option for people with advanced kidney cancer who cannot take standard therapies.
- What could go wrong
- This is an early Phase 2 study with only 60 participants, so results may not apply to everyone. The drug may cause side effects or fail to shrink tumors.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC CLEAR CELL RENAL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, 510060, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a pill rewrite the genetic story of resistant kidney cancer?
- Can a rapid drug switch outsmart advanced kidney cancer?
- Can a tracer that hunts unstable iron light up hidden tumors?
- New imaging agent aims to spot Hard-to-Find kidney cancer spread
- Can fasting two days a week slow kidney cancer? a new trial tests the idea
- New PET scan could reveal kidney cancer drug success in weeks, not months